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Two species of the Epstein-Barr virus-encoded latent membrane protein 2, LMP2A and LMP2B, are
generated by alternative splicing, each species having a distinct first exon. LMP2 transcription in undifferen-
tiated nasopharyngeal carcinoma (NPC), which is consistently associated with the Epstein-Barr virus, was
investigated. Fifteen NPC specimens were analyzed by Northern (RNA) blot and RNA-based polymerase chain
reaction; the LMP2A transcript was present in all specimens except one. In some specimens the LMP2B
transcript was also detected. Sequence analysis of LMP2 cDNAs obtained from two NPC specimens revealed
four mutations in exon 1 of the LMP2A transcript, which were present in both tumors and which resulted in
nonconservative amino acid changes. These data suggest that the LMP2 expressed in NPC is distinct from that
which is expressed in lymphoid cells.
Epstein-Barr virus (EBV) is a ubiquitous virus producing
a lifelong infection in most humans. In asymptomatic carri-
ers, known cell targets are the B lymphocytes and epithelial
cells in the salivary glands and pharyngeal mucosa (15). In
addition, EBV is suspected to play a causative role in several
human malignancies containing the viral genome, especially
nasopharyngeal carcinoma (NPC), the African endemic form
of Burkitt's lymphoma, and a fraction of Hodgkin lympho-
mas (8, 16, 18). The association of EBV with NPC is
particularly consistent in low- as well as in high-incidence
areas (1). While several malignant cell types can harbor the
EBV genome in vivo, only B lymphocytes can be infected in
vitro, resulting in the outgrowth of growth transformed
lymphoblastoid cell lines (LCLs). Most LCLs are predomi-
nantly latently infected and express a limited number of viral
genes, including the two small nuclear RNAs, EBER1 and
-2; six nuclear proteins, EBNA1, -2, -3A, -3B, -3C, and -LP;
and three membrane proteins, LMP1, -2A, and -2B (11).
To understand the possible contribution of EBV to NPC
oncogenesis, it is essential to characterize EBV expression.
In NPC specimens, linear viral genomes are not usually
detected, revealing that the EBV infection is predominantly
latent (17). Previous studies have identified differences be-
tween EBV gene expression in NPC cells and that in LCLs.
The EBNA1, LMP1, and the EBERS transcripts are ex-
pressed in NPC in the absence of expression of the other
EBNAs (3, 19). In addition, LMP1 can be expressed in NPC
from two forms of mRNA and a 4.8-kb mRNA transcribed
from the BamHI A fragment is consistently expressed in
NPC (5). The BamHI A RNA encodes a protein which is
precipitable with sera from patients with NPC (6).
The LMP2 gene contains exons located at both ends of the
linear EBV genome and can be transcribed only across the
fused termini of the episomal form or in some rare integrated
events (9, 12, 20). Two distinct forms of mRNA encode the
54- and 40-kDa LMP2 membrane proteins. The 2.3- and
2.0-kb RNAs have different promoters, and the two RNAs
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each have a unique first exon located in the UL region and
share exons 2 to 9 in the Us region. The first exon of LMP2A
(exon 1A) encodes the hydrophilic N terminus, whereas the
first exon of the B form (exon 1B) is noncoding. LMP2B
RNA has a translation initiation codon at the beginning of
exon 2 and codes for an extremely hydrophobic protein
which is much less antigenic than LMP2A. The possibility of
LMP2 expression in NPC was considered, as fused termini
can be detected in all NPC specimens (17, 18). In addition, it
has been recently shown that patients with NPC have
circulating antibodies directed to LMP2A (4).
Both NPCs transplanted into nude mice and fresh biopsy
samples were used in this study. Three of four transplanted
NPCs-C15, C17, and C18-have been described previously
(2). C19 has been obtained more recently. All four tumors
contain the EBV genome and display epithelial markers
(desmosomes and cytokeratin). Six fresh biopsy samples of
NPC lymph node metastases were obtained from distinct
untreated patients from Egypt, Taiwan, and Malaysia (Ml to
M6). Five fresh biopsy samples of NPC primary tumors were
obtained from another set of Egyptian patients (P1 to P5).
Tumors resulting from the growth of HeLa cells injected in
nude mice provided a negative control.
Identification ofLMP2A and -2B mRNAs in NPC. Northern
(RNA) blots were prepared with poly(A)+ RNA from the
transplanted NPCs and B95-8 cells which were either not
treated or induced for viral replication by treatment with
tetradecanoyl phorbol acetate (Fig. 1). The blots were hy-
bridized with an LMP2A cDNA riboprobe. This cDNA was
derived from the IB4 LCL, which carries the B95-8 EBV
strain; its sequence overlaps the unique LMP2A exon 1
(exon IA) and the exons 2 to 9 common to the A and B
transcripts (20). Although the LMP2A and -2B transcripts
could be distinguished in the B95-8 RNA exposed for 2 h, the
resolution was not as clear for the C15 and C17 LMP2
transcripts. However, the relative migration suggests that
the B and A forms are predominant in C15 and C17,
respectively. The 3-day exposure indicates that the LMP2
transcripts are less abundant in NPC than in B95-8 RNA.
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FIG. 1. Detection of LMP2 transcripts in transplantable NPCs by Northern hybridization. Frozen tissue samples were pulverized in a
microdismembrator, and total RNA was extracted by the guanidine-CsCl method. Poly(A)+-selected RNA (10 p.g) was subjected to
electrophoresis through an 0.8% agarose-formaldehyde gel, transferred to nitrocellulose, and hybridized with a full-length LMP2A cDNA
cloned in the pBluescript KS(+) plasmid (Stratagene, La Jolla, Calif.). Riboprobe synthesis, hybridization, and washing were performed as
previously described (5). (A) LMP2 hybridization (2-h exposure). Lanes: 1, B95-8 (B95) induced with tetradecanoyl phorbol acetate (TPA);
2, AG876 (EBV-positive Burkitt lymphoma cell line); 3, uninduced B95-8 (RNA preparation [prep] no. 2); 4, Louckes (EBV-negative Burkitt
lymphoma cell line); 5, uninduced B95-8 (RNA preparation no. 1). (B) Ethidium bromide staining. Lanes contain uninduced B95-8
(preparation no. 1) and transplanted NPCs (C15, C17, and C18). (C) LMP2 hybridization (3-day exposure). The filter shown represents the
samples presented in panel B. Filters displayed in panels A and C were hybridized simultaneously with the same probe.
levels in NPC than in B95-8 (5). The intensity of the 28S
ribosomal band was relatively weaker in the C18 channel
compared with the C15 and C17 lanes; however, the LMP2
transcripts could not be detected even in long exposures by
Northern blot analysis of C18 and C19 RNA (Fig. 1 and data
not shown).
PCR analysis ofLMP2 transcription in NPC. To investigate
LMP2 gene transcription in RNA obtained from biopsy
material or tissues passaged in nude mice, polymerase chain
reaction (PCR) was utilized to amplify across splice junc-
tions in cDNA preparations. This method does not require
the integrity of RNA necessary for identification on North-
ern blots and enables identification of specific transcription
in small amounts of material from fresh biopsy specimens,
which may consist of mixtures of EBV-negative normal
tissue with tumor tissue. Oligonucleotides which span the
approximately 2-kb intron which separates exons 1A and 1B
from exon 2 were prepared, allowing specific amplification of
processed mRNAs without competitive amplification of ge-
nomic DNA. Primer pairs were designed to give PCR
products diagnostic of LMP2A (309 bp) and LMP2B (301
bp). Both pairs included a specific 5' primer located in exon
1A or 1B and a common 3' primer located in the exon 2
(GATTGCAACACGACGGGAATG in exon 1A, coordi-
nates 166820 to 166840; CAGTGTAATCTGCACAAAGAG
in exon 1B, coordinates 169819 to 169839; and AAGTGAC
AACCGCAGTAAGCA in exon 2, coordinates 251 to 271; all
coordinates are from the genome of the B95-8 strain).
Another oligonucleotide from exon 2 was used as an internal
probe (TGTCACCGGTGTCAGCAGTTT, coordinates 229
to 249).
In poly(A)+ RNA of all the nude mouse passaged tumors,
both LMP2A and -2B PCR products could be detected (Fig.
2). Amplification was not detected in the EBV-negative
HeLa cell line control. In most samples, PCR products were
visible by ethidium bromide staining; nevertheless, they
were subsequently blotted and hybridized to an internal
end-labelled oligonucleotide probe to achieve a better sensi-
tivity and to verify authenticity. LMP2A was much more
abundant in C15 and C17 than in C18 and C19. In C17, C18,
and C19, but not in C15, the amount of LMP2B cDNA was
less than that of the LMP2A form. Comparison of the
actin-related counts measured at 18 and 22 cycles demon-
strates that at 18 cycles all samples were below the plateau of
amplification. At 18 cycles, actin amplification was less
efficient in C18 and C19 than in C15 material, with ratios of
approximately 1:2 to 1:3. In contrast, the ratios for LMP2
amplification varied from 1:10 to 1:80. This suggests that the
smaller amount of LMP2 amplified products in C18 and C19
samples reflects a smaller amount of LMP2 transcripts in
these tumors. These results are consistent with Northern
hybridization data.
Similar analyses of LMP2 transcription in cDNA synthe-
sized from total RNA obtained from fresh biopsy samples
indicated that the LMP2A and -2B transcripts were present
at variable levels in 10 of 11 and 3 of 11 fresh NPC biopsy
samples, respectively. The amplification of nine samples is
shown in Fig. 3. The actin cDNA amplification revealed less
mRNA in the M6 preparation than in the P2 preparation.
Two additional samples included Ml, which was positive for
LMP2A and -2B, and P1, which was positive for LMP2A
only (data not shown). One NPC specimen, M3, was nega-
tive for both LMP2A and -2B; however, control amplifica-
tions of the EBNA1 transcript were positive for all of the
tumor specimens except M3 (data not shown). The inability
to amplify any EBV mRNAs in the M3 tumor suggests that
the tissue specimen contained very small amounts of tumor.
Sequence analysis of the LMP2 transcript in NPC. To
determine the sequence of LMP2 in NPC, two overlapping
cDNAs were obtained from the C15 NPC by PCR cloning
(Fig. 4A). An additional small cDNA, E7-E8(C15), spanning
the intron between exons 7 and 8, was obtained from a C15
lambda gtll cDNA library which has been described previ-
ously (5) (Fig. 4A). The sequence of these cDNAs was
compared with the sequence of the prototype EBV strain,
B95-8. In exons 2 to 9, five base changes which resulted in
J. VIROL.
NOTES 3259
B-95 HELACIS C15 C17 CIB C19
LMP2A 4
% 154 0 100 103 170 12 5.5
L.MP2B I3b *
LMP2A . e m
B95 Mock Hela M.2 MI 3 M4 M15 Mt P2 P3 P4 PS
X 94 0 100 95 6.5 4.1 1.2
ww- -_ = _
23 6 1 1 00 143 7 1 45 50
ACTIN
(20 cycles)
M4 M15 IM65 P2
FIG. 3. Detection of LMP2 transcripts in fresh NPC specimens
by PCR amplification of cDNA and Southern hybridization. The
cDNAs were prepared from total RNA from fresh biopsy samples.
The mock PCR was done with water instead of cDNA. In most
samples, PCR products were visible by ethidium bromide staining;
nevertheless, they were subsequently blotted and hybridized with
an LMP2 riboprobe to achieve a better overall sensitivity. The input
cDNAs of the most abundant samples were monitored by 20 cycles
of actin cDNA amplification as described in the legend to Fig. 2.
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FIG. 2. Detection of LMP2 transcripts in transplanted NPCs by
PCR amplification of cDNA and Southern hybridization. First-
strand cDNA synthesis was primed by using 1 nmol of random
hexamers (Boehringer) annealed to 5 ,ug of total or poly(A)+ RNA.
Reverse transcription was done with Superscript reverse tran-
scriptase according to the instructions of the manufacturer (GIBCO-
Bethesda Research Laboratories, Gaitherburg, Md.). Newly synthe-
sized cDNA was diluted in 100 Il of water, aliquoted, and stored at
-20°C. PCR amplification was performed with a 5-pl aliquot of the
diluted cDNA solution, 0.8 U of AmpliTaq DNA polymerase
(Promega), and 25 pmol of each primer in a 25-pl reaction mixture
consisting of 200 FLM each deoxynucleoside triphosphate and a
standard PCR buffer. The following amplification program was used:
denaturation at 95°C for 30 s; annealing at 60°C for 1 min; and
extension at 72°C for 1 min. Thirty-five cycles were used for
amplification (in the first cycle, the denaturation step was extended
to 3 min). Aliquots of the PCR mixture were analyzed by electro-
phoresis through a 1.5% agarose gel. PCR products obtained with
two distinct C15 cDNA preparations are presented in each panel.
For all samples, the quality of the RNA preparation was controlled
by amplification of a cytoplasmic actin gene 202-bp product defined
by the following primer pair: sense primer CCTTCCTGGGCATG
GAGTCCT and antisense primer GGAGCAATGATC1ITGATC
TTC. The product was hybridized to an internal oligonucleotide
(CTGTGTTGGCGTACAGGTCTTT-GCGGATGT) (7). The amount
of radioactivity bound to the filter for each sample was quantitated
with the AMBIS radioanalytical imaging system (AMBIS Inc., San
Diego, Calif.). In each panel, the amount of radioactivity counted
for the first C15 preparation was chosen as an arbitrary index of
100%. B95, B95-8.
changes in 2 of 378 amino acids were identified (Table 1).
The mutation at base 77 results in the change of a proline to
a leucine. The mutation at bp 1438, a conservative change of
serine to threonine, was also detected in the E7-E8(C15)
cDNA.
In contrast to the conservation of exons 2 to 9, nine base
pair mutations resulted in changes in 8 of 119 amino acids in
exon 1A. Four of the mutations result in nonconservative
amino acid changes (Fig. 4B). Two mutations (coordinates
166627 and 166750) would replace a tyrosine by an aspartic
acid residue, introducing two additional negative charges.
One base change (coordinate 166747) would result in the loss
of a proline, while another mutation (coordinate 166805)
would result in the gain of one proline.
To determine whether exon 1A was similarly altered in
other NPCs, a cDNA which contains most of the exon 1A
sequence was cloned from the C17 tumor, in which LMP2A
is predominantly expressed. The sequence of exon 1A in C17
was essentially identical to that of the C15 cDNA. Six
identical amino acid changes were present in the sequenced
region (Fig. 4B). Interestingly, two base pair changes which
are distinct in C15 and C17 (166747 and 166748) affect the
same codon, resulting in nonconservative amino acid
changes of a proline to serine and leucine, respectively.
Northern and RNA-based PCR analyses indicate that the
LMP2 gene is consistently transcribed in NPC cells, with
detection in 14 of 15 specimens. LMP2B was detected in 4 of
4 transplantable NPCs but only in 3 of 11 fresh NPC biopsy
samples. The increased detection of LMP2B in the trans-
planted NPCs may reflect the enrichment of processed
mRNAs by selection of poly(A)+ RNA, whereas in fresh
biopsy samples only a small amount of total RNA was
available for study. Regardless, in fresh specimens with
detectable LMP2B products (Ml, P2, and P5), LMP2A
products were more or equally abundant. The C15 tumor
appears to be an exception, with more LMP2B than LMP2A.
Similarly, LMP2A appears to be the more abundant species
in LCLs and EBV-positive Burkitt lymphoma cell lines (22).
In contrast to results of a previous study, which suggested
that LMP2A was not transcribed in NPC, the data presented
here indicate that LMP2A is consistently transcribed in NPC
(21).
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only in primary tumors but also in metastases and in metas-
tases passaged in nude mice for a long time, suggests that
LMP2 expression may provide a proliferative advantage to
the malignant cells, even at advanced stages of tumor
progression.
It is at present unknown how LMP2 contributes to the
FIG. 4. LMP2 cDNA cloning and sequencing from the C15 and
C17 NPCs. (A) Schematic representation of cDNAs used for se-
quencing. (B) Comparison of LMP2 exon 1A sequences in C15, C17,
and the B95-8 (B-95) prototype strain. E1A-E2(C15) contains most
of the coding sequence of exon 1A and 2 (sense primer with an
EcoRI site: ACAGGAAlTCGT'ITGCAGTCGCTGCTGCA, coor-
dinates 166538 to 166557; antisense primer with an XbaI site:
GTAGTCTAGAAGTGACAACCGCAGTAAGCA, coordinates 251
to 271). E2-E9(C15) encompasses the coding sequence of exons 2 to
9 (sense primer with a PstI site: ACAGCTGCAGTGCCTGTAAT
TGTTGCGCCCT, coordinates 74 to 94; antisense primer with an
XbaI site: GTAGTCTAGAGTGAACAGAGCCCTGCAATGT, co-
ordinates 5502 to 5522). An additional cDNA called ElA-E2(C17)
was derived from the C17 mRNA by using the following pair of
primers: a sense primer with a PstI site, ACAGCTFGCA
GATGGGGTCCCTAGAAATGGTG, coordinates 166561 to 166581;
an antisense primer with an EcoRI site, GTAGGAATTCGGCQ
CAACAATTACAGGCAG, coordinates 73 to 92. For the synthesis
and cloning of each cDNA some modifications were introduced to
the protocols reported in the legend to Fig. 2B. For E2-E9(C15),
first-strand cDNA synthesis was primed with oligo-dT12-18 (1 nmol
for 5 ,ug of RNA); the amplification program included 35 cycles with
a denaturation step at 95°C for 1 min, annealing at 55°C for 2 min,
and extension at 72°C for 3 min (in the first cycle the denaturation
step was extended to 5 min). For ElA-E2(C15) and ElA-E2(C17)
amplification, the reaction included an analog of dGTP, 7-deaza-2'-
dGTP, as recommended to amplify some G-C rich sequences (10).
The PCR mixture included 150 puM c7dGTP, 50 ,uM dGTP, and 200
FM other dNTPs. Amplification products were gel purified by the
Geneclean method (Bio 101, La Jolla, Calif.), digested with the
appropriate combination of restriction enzymes, submitted again to
the Geneclean procedure, and finally used for directional cloning in
the pBS+ plasmid (Stratagene). Single-strand DNA was obtained
from plasmid DNA by alkaline denaturation and sequenced by the
dideoxy-chain termination method by using the Sequenase enzyme
(U.S. Biochemicals, Cleveland, Ohio) in the presence of the appro-
priate primers and 35S-ATP. Base pairs which are modified in C15
and/or C17 and amino acid substitutions are double underlined.
Numbers above mutated bases refer to numbers of changes as
shown in Table 1.
malignant state or the maintenance of EBV latency. The
LMP2A protein has two domains with distinct structural
characteristics and potential functions (12). The hydrophilic,
intracytoplasmic domain, encoded by exon 1A, is a substrate
for cellular tyrosine kinases and induces tyrosine phosphor-
J. VIROL.
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TABLE 1. Base pair polymorphisms observed in the sequence of the LMP2 gene in NPC cDNAs
Change no. Coordinate in cDNA Location Base change Amino acid changeB95-8 (coordinate)'
1 166558 ElA-E2(C15) 5'UTr G-*A
2 166576 ElA-E2(C15) Exon 1A A-G Met--Val (6)
3 166579 ElA-E2(C15) Exon 1A GA Val-Met (7)
4 166627 ElA-E2(C15), ElA-E2(C17) Exon 1A T-*G Tyr--Asp (23)
5 166747 E1A-E2(C15) Exon 1A C--T Pro--Ser (63)
6 166748 ElA-E2(C17) Exon 1A C-*T Pro-*Leu (63)
7 166750 ElA-E2(C15), E1A-E2(C17) Exon 1A T--G Tyr-*Asp (64)
8 166796 ElA-E2(C15), ElA-E2(C17) Exon 1A C-*A Thr--Asn (79)
9 166805 ElA-E2(C15), ElA-E2(C17) Exon 1A A--C Gln--Pro (82)
10 166810 ElA-E2(C15), ElA-E2(C17) Exon 1A C-*T Leu-+Leu (84)
11 77 ElA-E2(C15) Exon 2 C-T Pro-Leu (126)
12 99 ElA-E2(C15), E2-E9(C15) Exon 2 C-G Leu-Leu (133)
13 184 ElA-E2(C15), E2-E9(Cl5) Exon 2 C--T Leu-*Leu (162)
14 252 E2-E9(C15) Exon 2 G-T Val--Val (184)
15 1438 E2-E9(Cl5), E7-E8(C15) Exon 7 T-*A Ser-*Thr (444)
Nonconservative amino acid changes are underlined.
b S'UT, 5' untranslated region of LMP2A RNA.
ylation and binding of a 70-kDa cellular protein (13). The
hydrophobic membrane domain, encoded by exons 2 to 9,
has a secondary structure which suggests a membrane
transport function (14, 20). An ATP-binding motif at amino
acids 293 to 298 at one of the cytoplasmic turns suggests that
the membrane domain may have a function requiring nucle-
otide binding (13).
The data presented here indicate that the membrane
domain is highly conserved in comparison with the sequence
of LMP2 in B95-8, with changes in 0.5% of the amino acids.
This domain is more conserved than LMP1 in C15, which
has substitutions in 3.5% of the amino acids (5). In contrast,
the intracytoplasmic domain of LMP2 has changes in 6.5%
of the amino acids. The distribution of mutations observed in
C15 and C17 LMP2 genes suggests that the membrane
domain has identical functions in LCLs and NPC cells,
whereas the intracytoplasmic domain may differ, possibly
resulting in distinct interactions with cellular proteins.
Nucleotide sequence accession numbers. The GenBank ac-
cession numbers for the E1A-E2(C15), E1A-E2(C17) and
E2-E9(C15) cDNA sequences are M87777, M87778, and
M87779, respectively.
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